"Drug Costs" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The amount that a health care institution or organization pays for its drugs. It is one component of the final price that is charged to the consumer (FEES, PHARMACEUTICAL or PRESCRIPTION FEES).
| Descriptor ID |
D016527
|
| MeSH Number(s) |
N03.219.151.400.350 N05.300.375.300
|
| Concept/Terms |
Drug Costs- Drug Costs
- Cost, Drug
- Costs, Drug
- Drug Cost
|
Below are MeSH descriptors whose meaning is more general than "Drug Costs".
Below are MeSH descriptors whose meaning is more specific than "Drug Costs".
This graph shows the total number of publications written about "Drug Costs" by people in this website by year, and whether "Drug Costs" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2006 | 1 | 0 | 1 |
| 2012 | 0 | 1 | 1 |
| 2016 | 1 | 0 | 1 |
| 2017 | 1 | 2 | 3 |
| 2018 | 0 | 3 | 3 |
| 2022 | 0 | 1 | 1 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Drug Costs" by people in Profiles.
-
What will it take for an injectable ARV to change the face of the HIV epidemic in high-prevalence countries? Considerations regarding drug costs and operations. J Int AIDS Soc. 2023 07; 26 Suppl 2:e26106.
-
The costs of interventions for type 2 diabetes mellitus, hypertension and cardiovascular disease in South Africa - a systematic literature review. BMC Public Health. 2022 12 12; 22(1):2321.
-
Levofloxacin versus placebo for the prevention of tuberculosis disease in child contacts of multidrug-resistant tuberculosis: study protocol for a phase III cluster randomised controlled trial (TB-CHAMP). Trials. 2018 Dec 20; 19(1):693.
-
Impact of adverse drug reactions on the incremental cost-effectiveness of bedaquiline for drug-resistant tuberculosis. Int J Tuberc Lung Dis. 2018 08 01; 22(8):918-925.
-
Incremental Cost Effectiveness of Bedaquiline for the Treatment of Rifampicin-Resistant Tuberculosis in South Africa: Model-Based Analysis. Appl Health Econ Health Policy. 2018 Feb; 16(1):43-54.
-
Quantifying the direct public health care cost of systemic sclerosis: A comprehensive data linkage study. Medicine (Baltimore). 2017 Dec; 96(48):e8503.
-
Varying intervals of antiretroviral medication dispensing to improve outcomes for HIV patients (The INTERVAL Study): study protocol for a randomized controlled trial. Trials. 2017 Oct 13; 18(1):476.
-
Sustained reduction in antibiotic consumption in a South African public sector hospital; Four year outcomes from the Groote Schuur Hospital antibiotic stewardship program. S Afr Med J. 2017 Jan 30; 107(2):115-118.
-
Cutting the cost of South African antiretroviral therapy using newer, safer drugs. S Afr Med J. 2016 Dec 21; 107(1):28-30.
-
Cost and resource use of patients on antiretroviral therapy in the urban and semiurban public sectors of South Africa. J Acquir Immune Defic Syndr. 2012 Nov 01; 61(3):e25-32.